Study 201012: A Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With COPD
Phase of Trial: Phase II
Latest Information Update: 24 May 2017
At a glance
- Drugs Batefenterol (Primary) ; Umeclidinium/vilanterol
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
- 07 Oct 2016 Status changed from active, no longer recruiting to completed.
- 29 Jul 2016 Planned End Date changed from 1 Jul 2016 to 1 Sep 2016.